Article
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Oct 2017
Goetz Matthew P, Suman Vera J, Reid Joel M, Northfelt Don W, Mahr Michael A, Ralya Andrew T, Kuffel Mary, Buhrow Sarah A, Safgren Stephanie L, McGovern Renee M, Black John, Dockter Travis, Haddad Tufia, Erlichman Charles, Adjei Alex A, Visscher Dan, Chalmers Zachary R, Frampton Garrett, Kipp Benjamin R, Liu Minetta C, Hawse John R, Doroshow James H, Collins Jerry M, Streicher Howard, Ames Matthew M, Ingle James N
Abstract excerpt
Purpose Endoxifen is a tamoxifen metabolite with potent antiestrogenic activity. Patients and Methods We performed a phase I study of oral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity. Eligibility included endocrine-refractory, estrogen receptor-positive metastatic breast cancer. An accelerated titration schedule was applied until moderate or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.